CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2024 financial results after the market close on Wednesday, November 6, 2024. Catalyst's management team will host a conference call and webcast on T ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

文章核心观点 - 凯塔琳制药公司捐赠10万美元支持美国红十字会对受到"海伦"飓风影响的社区的救援工作 [1] - 公司表示,在危机时刻,对社区的承诺是坚定不移的,希望通过捐赠来确保受灾群众能获得所需的基本资源 [1] - 美国红十字会表示,感谢凯塔琳制药公司的慷慨捐赠,这将有助于为受到"海伦"飓风破坏的家庭提供帮助和希望 [1] 公司概况 - 凯塔琳制药公司是一家专注于罕见疾病领域的商业阶段生物制药公司,主要从事新疗法的引进、开发和商业化 [3] - 公司总部位于佛罗里达州珊瑚港,并被福布斯评选为2024年美国最成功的小型上市公司之一 [3] 飓风救援情况 - "海伦"飓风造成了广泛的破坏,导致受灾家庭急需支援 [1] - 美国红十字会已经动员了大规模的救援行动,在卡罗来纳州、田纳西州、佐治亚州和佛罗里达州,有超过1,400名红十字会救灾人员正在努力提供安全的住所、餐食和慰问 [1] - 凯塔琳制药公司的捐赠将有助于维持这些关键救援工作,为受灾群众带来希望 [1]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Catalyst Pharmaceuticals (CPRX) : This commercial-stage biopharmaceutical company which is focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 9.7% over the last 60 days. HCI Group (HCI) : This company which is engaged in diverse business activities, including property and casualty insurance, informat ...

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings e ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. - ...

Catalyst Pharmaceutical (CPRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a ...

CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE® (amif ...

文章核心观点 - 公司在欧洲和北美市场成功推出了AGAMREE治疗杜氏肌肉营养不良症的新药 [1][2][5][6] - 公司正在积极拓展AGAMREE在欧洲和中国的商业化 [3][7][8][9][10][11] - 公司正在进一步加强AGAMREE的临床开发 [12][13][14] 财务表现 - 公司上半年收入为1.41亿瑞士法郎 [15][16] - 公司上半年经营亏损为1770万瑞士法郎 [15][17][18][19] - 公司上半年净亏损为1530万瑞士法郎 [15][19] - 公司现金余额为1.65亿瑞士法郎 [15][19] - 公司完成了高达6900万瑞士法郎的融资 [23][24][25] 融资与展望 - 公司完成了高达6900万瑞士法郎的融资 [23][24][25] - 融资将为公司提供到2026年现金流平衡的资金支持 [25]

A month has gone by since the last earnings report for Catalyst Pharmaceutical (CPRX) . Shares have added about 8.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Catalyst due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Catalyst Q2 Earnings & Revenues Beat Estima ...